Non-invasive neuromodulation wearable digital therapeutic for treating Atrial Fibrillation, the world's most common cardiac arrhythmia with closed loop, AI based monitoring and therapy
Current Status
Working prototype, granted patents, results from first in Human clinical trials, Key Opinion leadership, machine learning algorithms.
Problem or Opportunity
We are addressing atrial fibrillation (AF). AF is the most common sustained arrhythmia, affecting 35 million people worldwide and projected to be 70M by 2050. In the US alone, there are 7 million patients with AF projected to become 11.5 M by 2025. AF is a progressive disorder and its incidence rises with age. One in four adults over 40 will develop AF in their lifetime. Today 8 out of 10 adults with AF are 65 or older. It is estimated that there are 500K new AF patients each year. In 2014 there were 537,801 AF related ER visits in the US and hospitalization rates are 70%. Re-visit rates to ER
Solution (product or service)
CardiaCare is a digital therapeutic company offering the world's first remote therapy delivery wearable for treating atrial fibrillation (AF) and potentially other cardiovascular conditions. The core differentiator is our ability to induce a mild vagal response by stimulating the wrist non-invasively. Leveraging over 10 years of clinical practice to create a company with broad domain expertise CardiaCare has several granted hardware and methods patents.
Business model
A physician prescribed device. Two revenue streams : 1. Sales of the Home Care wearable as prescription-based device . 2. Premium monthly app fee (SaaS model). Utilize existing reimbursement codes of long term parasympathetic therapy and codes of remote patient monitoring. Equipment/Capital Sales, Saas/Subscription Based, Freemium to Premium, Licensing Customer(s), Caregivers, Medical Device Manufacturers, Hospitals/Hospital Systems, Patients/Consumers
